Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Phase 3 Completed 1362 enrolled Takeda

RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with simvastatin on cholesterol levels in treating patients with elevated cholesterol.

Timeline

Start: 2006-03
Primary completion: 2007-05
Completion: 2007-05

Publications

Results Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011 May 10;123(18):1974-85. doi: 10.1161/CIRCULATIONAHA.110.975284. Epub 2011 Apr 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lapaquistat acetate	Small molecule	50 mg	Oral
Subject	Lapaquistat acetate	Small molecule	100 mg	Oral
Comparator	Simvastatin	Small molecule	—	Oral

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Summary

Timeline

Publications

Drugs

Indications